Amgen’s T-cell engager notches major new lung cancer victory
Amgen reported a key clinical win for its T cell engager platform, finding that Imdelltra combined with a checkpoint inhibitor helped patients with advanced lung cancer live longer. The California pharma company
September 8, 2026 01:53 PM EDT R&DPharma Amgen’s lung cancer treatment Imdelltra notches major new victory Max Bayer Senior Reporter Amgen reported a key clinical win for its T cell engager platform, finding that Imdelltra combined with a checkpoint inhibitor helped patients with advanced lung … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that